Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech firm's mRNA-1018 candidate posted positive ...